Atrial fibrillation in the elderly

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation (AF) is the most common arrhythmia in older adults, significantly increasing stroke risk.
• Anticoagulant use for stroke prevention in the elderly is challenging due to age-related increases in both stroke and bleeding risks.
• Current guidelines recommend CHA₂DS₂-VASc and HAS-BLED scores for risk stratification.

Purpose of the Study:

• To review current strategies for stroke prevention in elderly patients with atrial fibrillation.
• To discuss the role of anticoagulation and risk assessment scores in this population.
• To evaluate rate versus rhythm control and the use of newer antiarrhythmic drugs like dronedarone.

Main Methods:

• Literature review of guidelines and studies on atrial fibrillation management in the elderly.
• Analysis of risk stratification scores (CHA₂DS₂-VASc, HAS-BLED) for stroke and bleeding.
• Comparison of rate control versus rhythm control strategies and antiarrhythmic drug profiles.

Main Results:

• Anticoagulation is recommended based on CHA₂DS₂-VASc scores, with specific guidelines for scores of 1 or higher.
• Aspirin is no longer recommended for AF thromboprophylaxis.
• Lenient rate control is generally preferred in elderly patients due to fewer adverse effects and hospitalizations.
• Dronedarone may be considered for rhythm control in paroxysmal AF without heart failure, offering a better side effect profile than amiodarone.

Conclusions:

• Stroke prevention in elderly AF patients necessitates individualized risk assessment and tailored therapeutic strategies.
• Rate control is often favored, but rhythm control with agents like dronedarone can be beneficial in specific patient subsets.
• Careful consideration of drug efficacy, safety, and patient comorbidities is crucial for optimal AF management in older adults.